Hori Toshiyuki
Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Int J Hematol. 2006 Jan;83(1):17-22. doi: 10.1532/IJH97.05151.
OX40 belongs to the tumor necrosis factor receptor superfamily, and its expression is restricted to activated T-cells. Ligation of OX40 during T-cell-dendritic cell interaction is crucial for clonal expansion of antigen-specific T-cells and generation of T-cell memory. The ligand of OX40 (OX40L) is expressed not only on dendritic cells but also on other cell types, such as B-cells, vascular endothelial cells, natural killer cells, and mast cells. The pathophysiological relevance of this broad distribution needs further investigation. In particular, OX40L on vascular endothelial cells may play a role in inflammatory vasculitis as well as in atherosclerotic change. Recent studies with animal models have indicated the critical involvement of OX40 in the pathogenesis of a variety of immunologic abnormalities of inflammatory, autoimmune, infectious, allergic, and allotransplantation-related diseases. Blockade of OX40-OX40L interaction has been shown to prevent, cure, or ameliorate these diseases. In contrast, activation of OX40 is known to break an existing state of tolerance in malignancies, leading to a reactivation of antitumor immunity. These findings clearly suggest that the OX40/OX40L system is one of the most promising targets of immune intervention for treatment of these diseases.
OX40属于肿瘤坏死因子受体超家族,其表达仅限于活化的T细胞。在T细胞与树突状细胞相互作用期间,OX40的结合对于抗原特异性T细胞的克隆扩增和T细胞记忆的产生至关重要。OX40的配体(OX40L)不仅在树突状细胞上表达,还在其他细胞类型上表达,如B细胞、血管内皮细胞、自然杀伤细胞和肥大细胞。这种广泛分布的病理生理相关性需要进一步研究。特别是,血管内皮细胞上的OX40L可能在炎症性血管炎以及动脉粥样硬化改变中起作用。最近的动物模型研究表明,OX40在多种炎症、自身免疫、感染、过敏和同种异体移植相关疾病的免疫异常发病机制中起关键作用。已证明阻断OX40 - OX40L相互作用可预防、治愈或改善这些疾病。相反,已知激活OX40会打破恶性肿瘤中现有的耐受状态,导致抗肿瘤免疫的重新激活。这些发现清楚地表明,OX40/OX40L系统是治疗这些疾病最有希望的免疫干预靶点之一。